EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)VergleichsstudieOpen Access · CC BY-NC 3.0

Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial

Jong-Chan Youn iD, Eui-Soon Kim iD, Tae Ho Park, Young Soo Lee iD, Soon Jun Hong, Jin-Yong Hwang, Jung-Kyu Han, Jung-Woo Son, Chan Joo Lee, Jung Hyun Choi, Sung Uk Kwon, Seok Yeon Kim und 2 weitere

Drug Design, Development and Therapy · 2026-05 · Volume 20 · 1-12

DOI: 10.2147/dddt.s587488 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2026-05. Verfasst von Jong-Chan Youn und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Diseas…. Hauptthemen laut MEDLINE: Telmisartan, Amlodipine, Hypertension, Antihypertensive Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelmisartanAmlodipineHypertensionAntihypertensive AgentsBenzimidazolesBenzoatesHumansDouble-Blind MethodFemaleMaleMiddle AgedBlood PressureDrug CombinationsDose-Response Relationship, DrugAgedTreatment Outcome

Stichwörter der Autor:innen

S-amlodipineessential hypertensiontelmisartanupfront low-dose combination therapy

Substanzen

TelmisartanAmlodipineAntihypertensive AgentsBenzimidazolesDrug CombinationsBenzoates

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Repub…
  • Department of Cardiology, Dong-A University Hospital, Busan, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, Daegu Catholic University, Daegu, Republic of Korea.
  • Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

ORCID-Profile: Jong-Chan Youn, Eui-Soon Kim, Young Soo Lee

Zitieren

APA

Youn, J. C., Kim, E. S., Park, T. H., Lee, Y. S., Hong, S. J., Hwang, J. Y., Han, J. K., Son, J. W., Lee, C. J., Choi, J. H., Kwon, S. U., Kim, S. Y., Park, H. C., & Choi, S. H. (2026). Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. Drug Design, Development and Therapy, Volume 20, 1-12. https://doi.org/10.2147/dddt.s587488

Vancouver

Youn JC, Kim ES, Park TH, Lee YS, Hong SJ, Hwang JY, et al. Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. Drug Design, Development and Therapy. 2026;Volume 20:1-12. doi:10.2147/dddt.s587488

BibTeX
@article{Youn2026,
  author = {Youn, Jong-Chan and Kim, Eui-Soon and Park, Tae Ho and Lee, Young Soo and Hong, Soon Jun and Hwang, Jin-Yong and Han, Jung-Kyu and Son, Jung-Woo and Lee, Chan Joo and Choi, Jung Hyun and Kwon, Sung Uk and Kim, Seok Yeon and Park, Hwan-Cheol and Choi, Seung-Hyuk},
  title = {Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--12},
  doi = {10.2147/dddt.s587488}
}
Kostenlos starten →